OMERS ADMINISTRATION Corp Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

OMERS ADMINISTRATION Corp cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 34.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,392 shares of the specialty pharmaceutical company's stock after selling 6,600 shares during the period. OMERS ADMINISTRATION Corp's holdings in Jazz Pharmaceuticals were worth $1,526,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC increased its position in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $28,000. Allianz SE bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $29,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 130 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Robert W. Baird decreased their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $182.79.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan acquired 1,621 shares of the business's stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the transaction, the director now directly owns 101,621 shares of the company's stock, valued at approximately $10,466,963. The trade was a 1.62% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. This trade represents a 10.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,236 shares of company stock valued at $3,956,190. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $0.69 during trading on Wednesday, hitting $111.71. 176,182 shares of the stock traded hands, compared to its average volume of 1,085,544. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The firm has a 50-day simple moving average of $114.74 and a 200-day simple moving average of $122.01. The company has a market capitalization of $6.88 billion, a P/E ratio of 15.73, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the business posted $2.68 earnings per share. As a group, analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.